Scholar Rock SRRK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Apitegromab | $90.76M+14.4% | $89.8M+14.7% | $89.06M— | $90.22M— | $79.34M— | |
| Early Research | $6.43M+71.1% | $6.68M+119% | $5.86M+88.2% | $5.32M+46.2% | $3.76M-8.0% | |
| RD Expense Srk181 | $1.33M-84.0% | $2.41M-75.8% | $4.15M— | $5.85M— | $8.32M— | |
| RD Expense Srk439 | $6.45M-53.7% | $8.97M-22.9% | $13.78M— | $14.96M— | $13.93M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Scholar Rock break its business down?
- Scholar Rock (SRRK) reports research and development expense by product across 4 parts — Apitegromab, Early Research, RD Expense Srk181 and RD Expense Srk439. Each is extracted from the segment footnotes and tracked over time.
- Where does Scholar Rock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Scholar Rock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.